Optimizing the Treatment of Acute Lymphoblastic Leukemia in Younger and Older Adults: New Drugs and Evolving Paradigms

With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of acute lymphoblastic leukemia in both younger and older adults has substantially improved.